

Promising Type 1 Drug Spotlighted in Recent Issue of Forbes

Apr 2, 2008



Even the popular press is excited about recent developments involving anti-CD3, a potential type 1 therapy with strong ties to UCSF. In a recent issue of FORBES Magazine, senior editor Robert Langreth reveals the long history of anti-CD3 -- a monoclonal antibody that stops beta cell destruction.

In late 2007, history was made when two pharmaceutical companies entered into global alliances to develop and commercialize anti-CD3 drug therapies to treat and potentially to prevent type 1 diabetes: Eli Lilly and MacroGenics are developing teplizumab, and GlaxoSmithKline and Tolerx are developing otelixizumab. Of special significance ? anti-CD3 may be the first exclusively type 1 diabetes treatment to progress this far in drug development.

Please see the following [link](#) ^[1] for the original article.

Source URL: <http://diabetes.ucsf.edu/news/promising-type-1-drug-spotlighted-recent-issue-forbes>

Links:

[1] <http://www.forbes.com/forbes/2008/0211/062.html>